Stampidine

From Wikipedia, the free encyclopedia

Stampidine
Systematic (IUPAC) name
Methyl (2R)-2-[ [(4-bromophenoxy)- [ [(2S,5R)-5-(5-methyl-2, 4-dioxopyrimidin-1-yl)- 2,5-dihydrofuran-2-yl]methoxy] phosphoryl]amino]propanoate
Identifiers
CAS number  ?
ATC code  ?
PubChem 469782
Chemical data
Formula C20H23BrN3O8P 
Mol. mass 544.289 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Stampidine is an experimental nucleoside reverse transcriptase inhibitor (NRTI).

It is a derivative of d4T (stavudine, Zerit), and has been designed to avoid dependence on the rate limiting step of phosphorylation of stavudine to stavudine monophosphate. This is governed by the supply of thymidine kinase that is available, and stavudine is poorly phosphorylated to its monophosphate form in thymidine kinase-deficient cells. [1]

[edit] References

  1. ^ aidsmap.com | Stampidine


Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase
Inhibitors (NRTI)
Abacavir (ABC)° • Emtricitabine° • Lamivudine (3TC)° • Tenofovir° • Didanosine • Zidovudine (AZT) • Apricitabine† • Stampidine† • Elvucitabine† • Racivir† • Amdoxovir† • Stavudine‡ • Zalcitabine‡
Non-Nucleoside
Reverse Transcriptase
Inhibitors (NNRTI)
Protease Inhibitors (PI)
Entry/fusion inhibitors
Integrase inhibitors
Maturation inhibitors
Bevirimat† • Vivecon™†
Combined formulations
Other &
experimental agents
°DHHS preferred first-line agent. †Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent.